Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection?
作者信息
Clavien Pierre-A
出版信息
Ann Surg. 2007 Jun;245(6):843-5. doi: 10.1097/SLA.0b013e31805d0788.
Abstract
摘要
相似文献
1
Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection?干扰素：预防肝细胞癌切除术后复发的神奇子弹？
Ann Surg. 2007 Jun;245(6):843-5. doi: 10.1097/SLA.0b013e31805d0788.
2
A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.肝细胞癌切除术后辅助性干扰素治疗的一项随机对照试验。
Ann Surg. 2007 Jun;245(6):831-42. doi: 10.1097/01.sla.0000245829.00977.45.
3
Re: Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection?关于：干扰素：切除术后预防肝细胞癌复发的神奇子弹？
Ann Surg. 2008 May;247(5):900; author reply 900-1. doi: 10.1097/SLA.0b013e31816ff75c.
4
Summaries for patients. Does interferon-alpha prevent recurrence of malignant tumors in patients with hepatitis C - related liver cancer?
Ann Intern Med. 2001 May 15;134(10):S-7.
5
Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials.α干扰素治疗对肝细胞癌完全切除或消融术后复发及生存的影响：一项随机对照试验的荟萃分析
Int J Cancer. 2009 Jun 15;124(12):2982-8. doi: 10.1002/ijc.24311.
6
Interferon: benefit beyond hepatitis therapy?
Am J Gastroenterol. 2001 Dec;96(12):3435-6. doi: 10.1111/j.1572-0241.2001.05371.x.
7
Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.根治性切除术后辅助应用干扰素 Alfa-2b 的随机、观察对照、III 期临床试验的长期结果：肝细胞癌。
Ann Surg. 2012 Jan;255(1):8-17. doi: 10.1097/SLA.0b013e3182363ff9.
8
Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial.术后干扰素α治疗可延缓乙肝相关肝细胞癌根治性切除术后患者的复发并提高总生存率：一项随机临床试验
J Cancer Res Clin Oncol. 2006 Jul;132(7):458-65. doi: 10.1007/s00432-006-0091-y. Epub 2006 Mar 24.
9
Does interferon therapy for chronic hepatitis B reduce the risks of developing cirrhosis and hepatocellular carcinoma?
Hepatology. 1995 Oct;22(4 Pt 1):1336-8.
10
Interferon-α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma.根治性切除术后干扰素-α治疗可预防乙型肝炎病毒相关肝细胞癌的早期复发并改善生存。
J Surg Oncol. 2010 Dec 1;102(7):796-801. doi: 10.1002/jso.21741.
引用本文的文献
1
Hepatocellular Carcinoma: Surgical Management and Evolving Therapies.肝细胞癌：手术治疗与不断发展的治疗策略。
Cancer Treat Res. 2024;192:185-206. doi: 10.1007/978-3-031-61238-1_10.
2
IFN-α facilitates the effect of sorafenib via shifting the M2-like polarization of TAM in hepatocellular carcinoma.干扰素-α通过改变肝癌中肿瘤相关巨噬细胞的M2样极化来增强索拉非尼的疗效。
Am J Transl Res. 2021 Jan 15;13(1):301-313. eCollection 2021.
3
Dihydropyrimidine dehydrogenase predicts survival and response to interferon-α in hepatocellular carcinoma.二氢嘧啶脱氢酶预测肝癌患者的生存和对干扰素-α的反应。
Cell Death Dis. 2018 Jan 22;9(2):69. doi: 10.1038/s41419-017-0098-0.
4
Extracellular 2'5'-oligoadenylate synthetase 2 mediates T-cell receptor CD3-ζ chain down-regulation via caspase-3 activation in oral cancer.细胞外2'5'-寡腺苷酸合成酶2通过激活半胱天冬酶-3介导口腔癌中T细胞受体CD3-ζ链的下调。
Immunology. 2016 Feb;147(2):251-64. doi: 10.1111/imm.12560. Epub 2015 Dec 27.
5
Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells.一种合成的干扰素-α/胎盘生长因子-2正电荷肽杂合分子在胰腺癌细胞中的抗肿瘤潜力
Sci Rep. 2015 Nov 20;5:16975. doi: 10.1038/srep16975.
6
Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis.辅助性干扰素用于肝细胞癌的早期或晚期复发以及根治性治疗后肝细胞癌的死亡率：一项比较不同类型肝炎的荟萃分析
Mol Clin Oncol. 2014 Nov;2(6):1125-1134. doi: 10.3892/mco.2014.386. Epub 2014 Aug 12.
7
Systemic therapy of hepatocellular carcinoma: current status and future perspectives.肝细胞癌的全身治疗：现状与未来展望。
World J Gastroenterol. 2014 Mar 28;20(12):3087-99. doi: 10.3748/wjg.v20.i12.3087.
8
Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma.开发 miR-26 伴随诊断检测用于肝癌辅助干扰素-α治疗。
Int J Biol Sci. 2013;9(3):303-12. doi: 10.7150/ijbs.6214. Epub 2013 Mar 16.
9
Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma.血小板衍生生长因子-A 的上调是导致肝细胞癌重新开始干扰素 α 治疗失败的原因。
BMC Cancer. 2012 Oct 1;12:439. doi: 10.1186/1471-2407-12-439.
10
Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma.非常规低剂量索拉非尼治疗后的反应：1例复发性肝细胞癌患者的灌注CT诊断及随访
J Gastrointest Cancer. 2012 Sep;43 Suppl 1:S234-8. doi: 10.1007/s12029-012-9403-4.
本文引用的文献
1
A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.肝细胞癌切除术后辅助性干扰素治疗的一项随机对照试验。
Ann Surg. 2007 Jun;245(6):831-42. doi: 10.1097/01.sla.0000245829.00977.45.
2
Strategies for safer liver surgery and partial liver transplantation.更安全的肝脏手术和部分肝移植策略。
N Engl J Med. 2007 Apr 12;356(15):1545-59. doi: 10.1056/NEJMra065156.
3
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.丙型肝炎病毒肝硬化患者肝切除术后应用α-干扰素预防肝细胞癌复发
Hepatology. 2006 Dec;44(6):1543-54. doi: 10.1002/hep.21415.
4
Postresectional adjuvant intraportal chemotherapy in patients with hepatocellular carcinoma: a case-control study.肝细胞癌患者肝切除术后门静脉内辅助化疗：一项病例对照研究。
Ann Surg Oncol. 2006 Oct;13(10):1329-37. doi: 10.1245/s10434-006-9004-1. Epub 2006 Aug 5.
5
Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial.术后干扰素α治疗可延缓乙肝相关肝细胞癌根治性切除术后患者的复发并提高总生存率：一项随机临床试验
J Cancer Res Clin Oncol. 2006 Jul;132(7):458-65. doi: 10.1007/s00432-006-0091-y. Epub 2006 Mar 24.
6
Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?--no, never.我们应该扩大活体肝移植治疗肝细胞癌的标准吗？——不，绝不。
J Hepatol. 2005 Oct;43(4):573-7. doi: 10.1016/j.jhep.2005.07.017.
7
Third forum on liver transplantation. Living donor liver transplantation. Who needs it? How to do it? Who should do it?第三届肝移植论坛。活体肝移植。谁需要它？如何进行？谁来实施？
J Hepatol. 2005 Jul;43(1):11-2. doi: 10.1016/j.jhep.2005.05.001.
8
Prevention of hepatocellular carcinoma.肝细胞癌的预防
Semin Liver Dis. 2005;25(2):155-61. doi: 10.1055/s-2005-871195.
9
Surgical therapy of hepatocellular carcinoma.肝细胞癌的外科治疗
Eur J Gastroenterol Hepatol. 2005 May;17(5):497-503. doi: 10.1097/00042737-200505000-00005.
10
Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data.非环状维甲酸预防肝细胞癌患者发生第二原发性肿瘤。长期随访数据的更新分析。
Intervirology. 2005;48(1):39-45. doi: 10.1159/000082093.
Zotero 插件